ProCE Banner Activity

Advancing HIV Prevention and Care for Principal Populations: A Roundtable

In this on-demand webcast of a live roundtable, expert faculty consider the latest data on currently available and emerging PrEP options as they discuss how to tailor PrEP strategies for people at high risk for HIV and how advances in PrEP continue to be essential for addressing the unique prevention needs of each person. Then the faculty panel explores the effects of the COVID-19 pandemic on HIV care and how infectious disease healthcare professionals can work toward addressing the complex issues of structural racism in medicine that were underscored by COVID-19.

Released: October 26, 2021

Expiration: October 25, 2022

No longer available for credit.

Share

Faculty

Babafemi Taiwo

Babafemi Taiwo, MBBS

Assistant Professor
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Daniel R. Kuritzkes

Daniel R. Kuritzkes, 医学博士

科长,传染病科
布莱根妇女医院
Harriet Ryan Albee 医学教授
哈佛医学院
波士顿,马萨诸塞州

Darcy Wooten

Darcy Wooten, MD, MS

Professor of Medicine
Division of Infectious Diseases and Global Public Health
University of California, San Diego
San Diego, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Educational grant provided by

Merck Sharp & Dohme Corp.

ViiV Healthcare

Program Director Disclosure

Program Director

Babafemi Taiwo, MBBS

Assistant Professor
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi Taiwo, MBBS, has disclosed that he has received consulting fees from Gilead Sciences, Merck, and ViiV and funds for research support from Janssen.

Faculty Disclosure

Primary Author

Daniel R. Kuritzkes, 医学博士

科长,传染病科
布莱根妇女医院
Harriet Ryan Albee 医学教授
哈佛医学院
波士顿,马萨诸塞州

Daniel R. Kuritzkes, MD, has disclosed that he has received funds for research support rom Atea, Gilead Sciences, Merck, Novartis, and ViiV and consulting fees from Abpro, Atea, Decoy, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Rigel, and ViiV.

Darcy Wooten, MD, MS

Professor of Medicine
Division of Infectious Diseases and Global Public Health
University of California, San Diego
San Diego, California

Darcy Wooten, MD, has no relevant conflicts of interest to report.

Staff Disclosure

Staff

Sarah Anderson, PharmD

Scientific Director

Sarah L. Anderson, PharmD, BCACP, BCPS, FASHP, FCCP, has no relevant conflicts of interest to report.

Jennifer M. Blanchette, Ph.D.

Clinical Editor
Clinical Care Options, LLC

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.

Edward King, M.A.

Vice President, Editorial
Clinical Care Options, LLC

Edward King, MA, has no relevant conflicts of interest to report.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.

Julie Skowronski, FNP-BC

Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.